ILUMINATE: An Open-Label, Non-Interventional Study of the Safety and Effect of Iluvien (Fluocinolone Acetonide 190 Micrograms Intravitreal Implant in Applicator) in Patients With Chronic Diabetic Macular Edema (DME) Insufficiently Responsive to Available Therapies

Trial Profile

ILUMINATE: An Open-Label, Non-Interventional Study of the Safety and Effect of Iluvien (Fluocinolone Acetonide 190 Micrograms Intravitreal Implant in Applicator) in Patients With Chronic Diabetic Macular Edema (DME) Insufficiently Responsive to Available Therapies

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ILUMINATE
  • Sponsors Alimera Sciences
  • Most Recent Events

    • 07 Aug 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 03 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 13 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top